Danaher Co. (NYSE:DHR) Position Reduced by Woodmont Investment Counsel LLC

Woodmont Investment Counsel LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 0.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,838 shares of the conglomerate’s stock after selling 60 shares during the period. Woodmont Investment Counsel LLC’s holdings in Danaher were worth $3,569,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after buying an additional 139,989 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Danaher by 1.0% in the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock valued at $1,279,932,000 after buying an additional 52,679 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after buying an additional 85,081 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on DHR shares. Raymond James dropped their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Bank of America lifted their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Down 0.9 %

DHR stock opened at $247.81 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $192.35 and a 1 year high of $281.70. The company has a fifty day simple moving average of $265.79 and a 200 day simple moving average of $260.75. The firm has a market cap of $178.99 billion, a PE ratio of 47.29, a PEG ratio of 4.55 and a beta of 0.85.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Sell-side analysts anticipate that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is 20.61%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.90% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.